MedTrace Logo

An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma

NCT02473939 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2016-12-21

No results posted yet for this study

Summary

The purpose of the study is to Evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of VR942 in healthy subjects (part 1) and repeated doses in mild asthmatics (part 2).

Conditions

Interventions

DRUG

VR942 delivered via a Vectura Dry Powder Inhaler

DRUG

Placebo delivered via a Vectura Dry Powder Inhaler

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Vectura Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473939 on ClinicalTrials.gov